61MO IMscin001 (part 2: randomized phase III): Pharmacokinetics (PK), efficacy and safety of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC). (December 2022) - Burotto, M.; Zvirbule, Z.; Mochalova, A.; Runglodvatana, Y.; Herraez Baranda, L.A.; Liu, S.; Chan, P.; Shearer-Kang, E.; Shivhare, M.; Tosti, N.; Zanghi, J.; Leutgeb, B.; et al.